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Abstract  
As the last enzyme in nucleotide synthesis as precursors for DNA replication, thymidylate 
kinase of M. tuberculosis (MtbTMPK) attracts significant interest as a target in the discovery of 
new anti-tuberculosis agents. Earlier, we discovered potent MtbTMPK inhibitors, but these 
generally suffered from poor antimycobacterial activity, which we hypothesize is due to poor 
bacterial uptake. To address this, we herein describe our efforts to equip previously reported 
MtbTMPK inhibitors with targeting moieties to increase the whole cell activity of the hybrid 
analogues. Introduction of a simplified Fe-chelating siderophore motif gave rise to analogue 17 
that combined favorable enzyme inhibitory activity with significant activity against M. 
tuberculosis (MIC of 12.5 μM). Conjugation of MtbTMPK inhibitors with an imidazo[1,2-
a]pyridine or 3,5-dinitrobenzamide scaffold afforded analogues 26, 27 and 28, with moderate 
MtbTMPK enzyme inhibitory potency, but sub-micromolar activity against mycobacteria without 
significant cytotoxicity. These results indicate that conjugation with structural motifs known to 
favor mycobacterial uptake may be a valid approach for discovering new antimycobacterial 
agents. 
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Tuberculosis, caused by the infectious agent Mycobacteria tuberculosis (M. tuberculosis), leads 
to a high death rate with more than 1.2 million patients succumbing to the infection every year 
[1]. Over the past decade, the overall incidence of tuberculosis has declined, although regions 
in sub-Saharan Africa and Asia show alarmingly high incidence rates. The emergence of 
multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains threatens any achieved 
progress in combatting this disease [2]. The increasing number of drug-resistant tuberculosis 
places an unsustainable burden on health-care systems, in addition to affecting economical as 
well as societal growth.  
The approval of bedaquiline and delamanid by the EMA and FDA has provided new hope for 
afflicted patients, but the first M. tuberculosis isolate resistant to bedaquiline was reported 
shortly after clinical introduction of this drug [3]. Very recently pretomanid has been approved 
as a combination partner for bedaquiline and linezolid in treating highly resistant forms of TB 
[4]. Nonetheless, this regimen is contra-indicated in patients with hypersensitivity to bedaquiline 
or linezolid, effectively narrowing its use. Taken together, research efforts toward the discovery 
and development of new antitubercular agents, particularly those with a novel mechanism of 
action, should be actively pursued to keep pace with the high incidence of tuberculosis [5]. 
M. tuberculosis thymidine monophosphate kinase (MtbTMPK), the last specific enzyme in the 
biosynthesis of thymidine triphosphate, is indispensable for mycobacterial growth and survival 
[6]. A crystal structure [7] of the protein has been reported, showcasing a unique configuration 
of its active site [6], making MtbTMPK a promising target to pursue for the discovery of new 
bio-active molecules to treat tuberculosis. 
Previous studies have described nucleoside [8-12] and non-nucleoside [13] MtbTMPK 
inhibitors. Even though these campaigns resulted in potent MtbTMPK inhibitors [8-12,14-17], 
these mostly suffered from low to moderate whole-cell activity. For a MtbTMPK inhibitor to show 
an antimycobacterial effect, it must cross both the inner and outer membranes to reach 
cytosolic concentrations to allow sufficient target enzyme inhibition to effect mycobacterial 
growth inhibition. While the required physicochemical properties for intracellular accumulation 
has been studied in some detail for Gram-negative bacteria [18-20], this remains speculative 
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for mycobacteria.  
Mycobacteria rely on the secretion of low molecular weight siderophores to chelate and 
subsequently capture iron (Fe3+), which constitutes an essential nutrient for bacterial growth 
[21]. The receptor-mediated active import of siderophores turns these into possible antibiotic 
delivery vectors [22-24]. Typically, a siderophore-mediated drug delivery system is comprised 
of an Fe-targeting siderophore moiety, an antibiotic and a connecting linker (Figure 1). Based 
on the stability of the linker, these conjugates can be further divided into non-releasable (stable) 
and releasable (liable) ones (Figure 1) [25]. In response to low-iron conditions present in the 
host, M. tuberculosis secrets two salicylate-derived siderophores, namely carboxymycobactin 
and mycobactin [26]. To date, only the latter has been successfully used as drug delivery vector 
[27]. In order to reduce the inherent complexity, simplified single bidentate ligands such as 
catechol or hydroxypyridone might be considered as surrogates, since their utility has already 
been demonstrated in Gram-negative bacteria [28-31]. In this study we explore the use of 
simplified siderophores to facilitate TMPK inhibitor uptake in M. tuberculosis.  
 
Figure 1. Generalized structure of a siderophore mediated drug delivery system and two 
successful examples of siderophore conjugation: the mycobactin-artemisinin conjugate and the 
single bidentate catechol-cephalosporin conjugate S-649266 [27,28].  
In the past decade new chemical entities emerged with promising whole-cell activity against M. 
tuberculosis. Imidazo[1,2-a]pyridine analogue Q203 [32] was reported as a promising 
antimycobacterial agent targeting the respiratory cytochrome bc1 complex (Figure 2). 
Nitroaromatic compounds such as 3,5-dinitrobenzamides [33] were also found to exhibit 
excellent antimycobacterial activity. The fact that both compounds share a N-substituted 4-
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arylpiperidine scaffold with our previously reported MtbTMPK inhibitor 1 [12] (Figure 3), inspired 
us to synthesize hybrid compounds of the latter that comprise the imidazo[1,2-a]pyridine and 
3,5-dinitrobenzamide moieties anticipated to be favourable for mycobacterial uptake.  
 
Figure 2. Structures of anti-TB scaffold of Q203 and 3,5-dinitrobenzamide. 
In this study we thus sought to combine the scaffold of previously reported MtbTMPK inhibitors 
with either simplified Fe-chelating motifs [26,34-36] or motifs from compounds with known 
whole-cell antimycobacterial activity, e.g. imidazo[1,2-a]pyridine and 3,5-dinitrobenzamide, and 
evaluate the effect of the resulting hybrid compounds on MtbTMPK inhibitory activity and in 
vitro anti-TB activity. An overview of the target analogues is presented in Figure 3. 
 
Figure 3. Compounds synthesized and evaluated in this study. A: Q203-based hybrids; B. 3,5-
dinitrobenzamide hybrids; C: non-cleavable siderophore hybrids; D. cleavable siderophore 
hybrids and their precursors.  
 
Results and discussion 
Chemistry  
Generally, the envisioned analogues were obtained through either reductive amination of N3-
BOM-protected 1-(piperidin-4-yl)thymine with an appropriate aldehyde [12], or via alkylation of 
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the same intermediate with a suitable benzyl bromide derivative [37], followed by TFA-mediated 
BOM deprotection (Scheme 1) [11,12,38]. Preparation of the 4-quinolone derivative 4 was 
achieved by reductive amination of in situ generated aldehyde from 4-chloro-2-methylquinoline, 
and treatment of the resulting 4-chloroquinoline intermediate 3 with acetic acid at 125 °C [39], 
after multiple attempts to achieve substitution under basic conditions were met with failure (data 
not shown). 4-Substituted quinoline derivatives 6-10 were prepared by nucleophilic aromatic 
substitution [40] of 3 with different nucleophiles at 180 °C followed by BOM-deprotection.  
The 8-hydroxyquinoline derivative 13, on the other hand, was prepared via alkylation of 5 with 
an in situ generated benzyl bromide reagent derived from 2-methylquinolin-8-ylacetate, 
followed by global deprotection under acidic conditions. 
Scheme 1. 
 
Reagents and conditions: (a) (i) SeO2, 1,4-dioxane, reflux; (ii) 5, sodium 
triacetoxyborohydride, 1,2-dichloroethane, 32%; (b) (i) acetic acid, 125 ℃; (ii) neat TFA, 73 ℃, 
58%; (c) (i) RXH, EA, 180 ℃; (ii) neat TFA, 73 ℃, 10-50%; (d) (i) NBS, AIBN, CCl4, 80 ℃; (ii) 
5, K2CO3, ethanol, reflux, 20%; (e) neat TFA, 73 ℃, 58%. 
The synthesis of bipyridyl analogue 17 commenced with a Stille coupling between 6-
bromopicolinaldehyde and 2-(tributylstannyl)pyridine to deliver aldehyde 15 [41], which was 
subsequently reduced (Scheme 2). The resulting alcohol was transformed into its mesylate and 
immediately substituted with 5 and BOM-deprotected to afford the desired 17.  
Several intermediates described above (3, 7-10) were employed for the quinolone-based iron 
chelating ester/amide analogues 18-21 or hydrazine derivative 22. Compounds 18 and 19 were 
obtained by esterification of 9 and 10 with 3,4-bis(benzyloxy)benzoylchloride, followed 
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hydrogenolysis. A similar reaction sequence failed to produce 20, since the hydrogenolysis 
conditions (H2/Pd) led to benzoyl ester hydrolysis. To circumvent this issue, 7 was coupled with 
3,4-bis((tert-butyldimethylsilyl)oxy)benzoic acid, from which the tert-butyldimethylsilyl group 
could be easily removed with HF·pyridine. Hydroxamate 21 was obtained by coupling 8 with 
BnONH2.HCl and subsequent hydrogenolysis. Nucleophilic aromatic substitution of 3 with 2,4-
dihydroxybenzaldehyde at 180 °C, followed by reaction with methyl hydrazinecarbodithioate 
[42] furnished the desired hydrazine 22   
Scheme 2.  
 
Reagents and conditions: (a) Pd(PPh3)4, 2-(tributylstannyl)pyridine, toluene, reflux, 40%; (b) 
sodium triacetoxyborohydride, 1,2-dichloroethane, 49%; (c) (i) methanesulfonyl chloride, Et3N, 
CH2Cl2; (ii) 5, K2CO3, ethanol, 80 ℃; (iii) neat TFA, 73 ℃, 26%; (d) (i) 3,4-bis(benzyloxy)benzoyl 
chloride , N-methylmorpholine, CH2Cl2; (ii) Pd/C, H2, EtOH. 21%; (e) (i) EDC.HCl, DMAP, 3,4-
bis((tert-butyldimethylsilyl)oxy)benzoic acid, CH2Cl2; (ii) HF·pyridine, pyridine, THF, 0 ℃, 16%; 
(f) (i) EDC.HCl, DMAP, BnONH2.HCl, CH2Cl2; (ii) Pd/C, H2, EtOH, 20%; (g) (i) 2,4-
dihydroxybenzaldehyde, EA, 180 ℃; (ii) neat TFA, 73 ℃; (iii) methyl hydrazinecarbodithioate, 
MeOH, reflux, 6%.  
To access compounds featuring imidazo[1,2-a]pyridine amide or 3,5-dinitrobenzamide motifs, 
intermediate 5 was directly coupled to 6-chloro-2-ethylimidazo[1,2-a]pyridine-3-carboxylic acid 
to give amide 23 after BOM- deprotection. Alternatively, 5 was first reacted with 4-
fluorobenzonitrile or reductively alkylated with 4-cyanobenzaldehyde to yield 24 and 25, 
respectively (Scheme 3). BOM-deprotection and subsequent reduction of the nitrile with 
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NaBH4/CoCl2 gave rise to the benzylamine intermediates, which were amidated to the desired 
final compounds 26-28.  
Scheme 3.  
 
Reagents and conditions: (a) (i) EDC.HCl, HOBt, Et3N, 6-chloro-2-ethylimidazo[1,2-
a]pyridine-3-carboxylic acid, DMF, 70 ℃; (ii) neat TFA, 73 ℃, 21%; (b) n = 0, K2CO3, 4-
fluorobenzonitrile, DMSO, 120 ℃; n = 1, p-cyanobenzaldehyde, sodium triacetoxyborohydride, 
1,2-dichloroethane, 41%; (c) (i) neat TFA, 73 ℃; (ii) NaBH4, CoCl2, THF/H2O; (iii) 6-chloro-2-
ethylimidazo[1,2-a]pyridine-3-carboxylic acid, EDC.HCl, HOBt, Et3N, DMF, 70 ℃, 28%; (d) (i) 
neat TFA, 73 ℃; (ii) NaBH4, CoCl2, THF/H2O; (iii) 3,5-dinitrobenzoic acid, EDC.HCl, HOBt, Et3N, 
DMF, 70 ℃, 10-20%. 
Biological activity 
Enzyme inhibition 
All target compounds were tested for MtbTMPK inhibitory activity, including the 
precursors/potential degradation products of cleavable iron chelator MtbTMPK inhibitors, i.e. 4, 
7, 9 and 10 (Table1). Unexpectedly, all these precursors exhibited better enzyme inhibitory 
activity than compound 1 [12]. It is noteworthy that the hydroxyethyl amine 10 displays almost 
5-fold better activity than its hydroxyethyl ether analogue 9.  
Table 1. The MtbTMPK enzymatic activity of compounds. 
Compound IC50 (μM) Compound IC50 (μM) 
1 29 ± 3 19 0.24 ± 0.02 
4 7.8 ± 0.4 20 0.18 ± 0.02 
6 1.3 ± 0.1 21 1.0 ± 0.1 
7 0.83 ± 0.05 22 0.31 ± 0.02 
9 2.4 ± 0.3 23 879 ± 122 
 9 
10 0.53 ± 0.02 26 47 ± 7 
13 23 ± 2 27 NDa 
17 34 ± 5 28 48 ± 2 
18 0.14 ± 0.01   
aND: Not determined, due to precipitation. 
Interestingly, the inhibitory potency generally increased upon introduction of catechol (pairs 
9/18, 10/19, 7/20). To gain insight in their putative binding mode, 9 and 18 were docked into the 
enzyme (Figure 4, PDB: 5NR7 [12]). These studies suggest that hydroxyethyl ether in 9 forms 
a weak electrostatic interaction with Tyr39. Yet, the additional catechol ester of 18 protrudes 
outward the active site and may form hydrogen bonds with Asp9, Lys13 and Arg95, thereby 
stabilizing a bent conformation and resulting in an improved inhibitory activity. 
 
Figure 4. A. Structure of 9 docked in the active site of MtbTMPK (PDB: 5NR7 [12]). MtbTMPK 
is shown in a pale yellow cartoon representation with selected side chains labeled and shown 
as sticks with carbon atoms colored orange. Inhibitor 9 is drawn in stick representation with 
carbon atoms in pink, hydrogen-bonding interactions are shown as black dotted lines. B. 
Docking pose of inhibitor 18 in MtbTMPK (PDB: 5NR7 [12]) catalytic pocket. The protein is 
depicted as pale yellow cartoon representation with selected side chain labeled (orange). 
Inhibitor 18 is drawn in stick representation with carbon atoms in white. 
Except for bipyridyl analogue 17, the non-cleavable chelator hybrid analogues 21 and 
especially 22 displayed promising inhibitory potency.  
In line with earlier observations for other piperidine amide analogues [11,43], amide 23 showed 
very poor inhibitory potency. However, the insertion of a phenylmethylene group between the 
piperidyl and amide group as in 26 resulted in a 19-fold better potency. Since 26 structurally 
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deviates from all previous analogues, its co-crystal structure with MtbTMPK was determined at 
1.9 Å resolution (Table S2, PDB code: 6YT1). The crystal structure shows that 26 binds into the 
catalytic pocket contacting the same residues as analogous compounds (Figure 5A&B). 
Compound 26 is mainly accommodated by π−π electron stacking interactions above and below 
the plane of the heterocyclic system mediated by Tyr39, Tyr103, and Phe70, and is further 
stabilized by polar interactions mediated by Arg74 and Asn100 (Figure 5B). Surprisingly, 
compound 26 has the ability to engage residues of a symmetry-related TMPK protomer 
including Tyr39 and His53. This binding mode brings two antiparallel-oriented molecules of 26 
in close proximity to each other (Figure 5A). To investigate whether this unusual phenomenon 
might be due to a particular tendency of compound 26 to pre-organize, the X-ray structure of 
compound 26 alone was also determined (Figure 5C and 5D). In this structure the relative 
organization of two inhibitor molecules does not resemble the antiparallel orientation observed 
in the complex with the protein. However, similar π - π stacking between the two central phenyl 
rings of two neighboring compounds was observed in both structures, which may account for 
the unusual phenomenon seen in the structure with the protein. In the catalytic pocket, 26 
adopts an L-shaped (torsion angle 96º) conformation with the amide tail toward the α7- helix, 
which is distinct from the docked pose of 9 in which the hydroxyethyl tail protrudes to the α2- 
helix. While similar to 9, the thymine ring adopts an identical pose in the catalytic pocket of the 
enzyme (Figure 5B) and a π-alkyl interaction between a 4-piperidine ring and Leu52 was 
observed. The amide tail fails to show specific interactions, possibly accounting for the 
moderate inhibitory activity of 26. Encouraged by this finding, the 3,5-dinitrobenzamide 
analogues 27 and 28 were also prepared. Whereas the inhibitory potency of 27 could not be 
determined due to solubility problems in the MtbTMPK assay, 28 showed similar inhibitory 
potency as 26.  
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Figure 5. A. Co-crystal structure of compound 26 in complex with MtbTMPK at 1.9 Å resolution. 
One TMPK protomer in the asymmetric unit (pale yellow) is shown in cartoon representation 
together with a symmetry related protomer (pale green). Two symmetry-related molecules of 
compound 26 are shown in stick representation with carbon atoms in white. B. View of binding 
mode and interaction of compound 26 in the MtbTMPK active site. MtbTMPK is shown in a pale 
yellow cartoon representation. Compound 26 (carbon atoms in white) and the side chains of 
MtbTMPK interacting residues (carbon atoms in orange) are depicted as sticks. Hydrogen 
bonds are depicted as black dotted lines. The unbiased Fo-Fc difference electron density 
(contoured to +3 sigma) calculated before adding the ligand in the refinement process is shown 
as a green mesh. C. Crystal structure of compound 26. D. Packing in the crystal structure and 
unit cell of compound 26. 
 
Stability of cleavable MtbTMPK inhibitors 
The stability of selected compounds 19, 20 and 22 in ammonium bicarbonate-formic acid buffer 
solution (pH 6.6) was analyzed by LC-MS over the course of 24 h, and the results are 
summarized in Figure 6. Less than 10% degradation was found for inhibitor 20 and 22 up to 6 
h. At 24 h, the percentage of compounds remaining in buffer were above 70% for all three 
inhibitors. These data reflect that although ester (19) and hydrazine (22) derivatives are 
hydrolyzed, it is not instantaneous, which is the desired profile. Analogue 20 did not show 
significant hydrolysis over the entire time course of the experiment.  
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Figure 6. 24 h stability of inhibitors 19 (blue line), 20 (red line) and 22 (green line) in ammonium 




All the target compounds were also evaluated their antitubercular activity (Table 2). The 
precursor and most iron chelator containing compounds failed to show antimycobacterial 
activity. However, the (2,2'-bipyridin)-6-ylmethyl derivative 17 displayed a MIC value of 12.5 μM 
in 7H9/glucose medium, despite its moderate MtbTMPK inhibitory potency. Only 22 displayed 
better activity in GAST (Fe (-)) medium compared to GAST (Fe (+)). In line with previous 
piperidine amide analogues [11,12] and its very weak on-target activity, compound 23 lacked 
antimycobacterial activity. Interestingly, compound 26, which also features an imidazo[1,2-
a]pyridine motif but more remote from the piperidine ring, displayed a MIC of 4.7 μM in standard 
medium. Likewise, the dinitrobenzamide derivatives 27 and 28 exhibit low micromolar whole-
cell activity, and remain active in BSA containing medium (Table S3). Additionally, none of the 






Table 2. Antimycobacterial activity (H37Rv) of compounds in this study.  
 Mtb H37Rv MICa (μM)  
Compound  7H9/glucose GAST (Fe(+)) GAST (Fe(-)) MRC-5 CC50(μM) 
1 >64b - - - 
4 >100 >100 >100 >64 
6 >100 100 ≥100 >64 
7 ≥100 >100 ≥100 >64 
9 >100 >100 >100 >64 
10 >100 >100 >100 >64 
13 75 >100 >100 53.98 
17 12.5 >100 >100 >64 
18 ≥100 >100 >100 6.39 
19 >100 >100 100 >64 
20 >50 37 - - 
21 >50 50 - 32.22 
22 >100 100 25 1.45 
23 >100 >100 >100 >64 
26 4.7 2.3 - >64 
27 9.4 0.78 1.2 >64 
28 9.4 9.4 6.25 >64 
Isoniazid 0.15 0.15 0.15 - 
aMinimum inhibitory concentration (MIC) is the minimum concentration required to inhibit >99% 
growth of M. tuberculosis H37Rv in liquid culture. bReported IC50, which was tested on H37Ra 
strain. 
Conclusion  
The overall goal of this study was to synthesize hybrid compounds fusing or merging potential 
iron chelating moieties or motifs of compounds with known whole-cell antitubercular activity 
with earlier identified MtbTMPK inhibitors, as to increase the bacterial uptake. Unexpectedly, 
the subset of iron chelating hybrids generally showed increased MtbTMPK inhibitory potency, 
but only for 22 this resulted in moderate whole-cell antitubercular activity in iron-deficient GAST 
medium. A possible explanantion for the lack of whole-cell activity in this subset is that natural 
siderophores like mycobactin consist of multiple bidentate ligands for stoichiometric binding of 
iron(III), which is not the case for the simplified chelating moieties used in this study. Further 
analysis of their uptake by M. tuberculosis would assist active anti-tubercular agents 
identification, which will be done in future reserch. 
However, we were more succesfull with hybrids containing imidazo[1,2-a]pyridine and 
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dinitrobenzamide motifs. While merging these motifs with a known MtbTMPK inhibitor did not 
improve activity against the target, it afforded several non-toxic compounds (e.g. 26, 27 and 28) 
with promising antimycobacterial activity in all tested media. While at this stage we cannot 
exclude that this whole-cell activity is due to modulation of additional targets. Nevertheless, this 




Expression and purification of MtbTMPK 
MtbTMPK was expressed and purified as previously described [44]. In short, the pHL50 vector 
containing the coding sequence of wild-type MtbTMPK was used to transform E. coli BLi5 
competent cells. Transformed cells used to inoculate 1 L of 2XYT medium supplemented with 
antibiotics. The cells were allowed to grow at 37 °C, and protein production was induced with 1 
mM isopropyl-1-thio-β-D-thiogalactoside when the culture reached an absorbance of 1.5 at 600 
nm. After 3 h of incubation at 37 °C, cells were harvested by centrifugation at 8000g at 4 °C 
and stored at −80 °C. Cells from 1 L of culture were resuspended in 50 mL of cold lysis buffer 
containing 50 mM Tris HCl pH 8.0 supplemented with an antiprotease cocktail (Roche) and 
disrupted by sonication. After centrifugation at 20000g for 30 min at 4 °C, the filtered bacterial 
lysate was loaded on a 5 mL Blue-Sepharose column pre-equilibrated with lysis buffer. The 
column was washed with lysis buffer and most of the protein was eluted with elution buffer 
containing 50 mM Tris HCl pH 8.0, 1 M NaCl. A second elution was performed using elution 
buffer containing 50 mM Tris HCl pH 8.0, 2 M NaCl. Fractions containing MtbTMPK were pooled 
and injected on a HiLoad Superdex 75 16/600 column equilibrated with 20 mM Tris HCl pH 7.4, 
1 mM EDTA as a further polishing and buffer exchange step. Fractions containing pure 
MtbTMPK were pooled and Tris(2-carboxyethyl)-phosphine (TCEP) was added to 1 mM final 
concentration before flash-freezing the protein samples in liquid nitrogen. 
Crystal structure of MtbTMPK in complex with compound 26 
Before each cocrystallization experiment, MtbTMPK samples were thawed and concentrated 
to 8 mg/mL. Compound 26 was initially dissolved in 100% DMSO at a concentration of 100 mM 
and diluted to 50 mM with pure isopropanol. Diluted compound was added to the concentrated 
 15 
protein stock and incubated for 1 h at room temperature. Cocrystallization conditions of 
MtbTMPK-inhibitor complexes were screened at 20 °C by the sitting-drop vapor-diffusion 
method using a 1:1 protein/solution volume ratio and available commercial screens. 
Crystals of MtbTMPK in complex with compound 26 were obtained in condition H2 of 
commercial PEG/ION screen containing 0.05 M citric acid, 0.05 M BIS-TRIS propane pH 5.0 
and 16% w/v polyethylene glycol 3,350. Crystals were cryoprotected in mother liquor 
supplemented with ethylene glycol at a final concentration of 15%. Data collection on crystals 
of MtbTMPK in complex with compound 26 was achieved at the Proxima1 beamline at the Soleil 
synchrotron (Paris, France) at a wavelength of 0.97857 Å and a temperature of 100 K on a 
Dectris Pilatus 6 M pixel detector.  
Processing, indexing and scaling of the dataset was performed using XDS/ XSCALE [45], 
followed by mtz conversion with XDSCONV. 
The structure was solved by molecular replacement using the pdb of 5NQ5 as initial model 
using PHASER (Table S2) [12]. The structure was further refined by one cycle of rigid-body 
refinement in BUSTER (https://www.globalphasing.com/buster/) followed by positional and 
individual isotropic B-factor refinement in BUSTER and PHENIX [46]. During the course of 
refinement the model was manually improved in COOT [47]. NCS torsion restraints were used 
during the refinement. The grade Web Server (http://grade.globalphasing.org) was used to 
generate ligand coordinates as well as energy minimization and restraint generation. 
Ligand molecules were modeled in sigma-weighted Fo-Fc difference electron density maps in 
the course of the refinement. TLS refinement with TLS group definition defined by the TLSMD 
server was applied in the latest stages of refinement. 
The quality of the final crystal structures was assessed with MOLPROBITY [48] prior to 
deposition in the PDB database (www.rcsb.org) with accession code 6YT1. 
Enzymatic assay  
After expression and purification of MtbTMPK as described by Munier-Lehmann et al. [44], the 
enzymatic assay was conducted as previously reported [12]. Briefly, at fixed concentration of 
ATP (0.5 mM) and dTMP (0.05 mM), compounds were evaluated at different concentrations 
using the spectrophotometric assay described by Blondin et al [49]. The reaction medium 
consists of 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol 
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pyruvate, and 2 units each of coupling enzymes (lactate dehydrogenase, pyruvate kinase and 
nucleoside diphosphate kinase). IC50 value was calculated using Kaleida Graph to plot and fit 
the experimental data points. 
Computational studies. 
AutoDock vina and AutodockTools-1.5.6. [50] were used for the molecular modeling, with 
publicly available X-ray structure of the MtbTMPK (PDB entry 5NR7 [12]). After being minimized 
the energy (minimum RMS gradient: 0.001), the PDB files of all ligands were generated in 
ChemDraw 3D 16.0. The PDBQT files of the ligands and receptor were prepared by 
AutodockTools-1.5.6, including atom types, atomic partial charges and the information on the 
ligand torsional degrees. Centered on MtbTMPK active site PHE70 CE2 (the coordinates x, y, 
z were -0.997, 26.240, -4.528 correspondingly), the prepared PDBQT files of ligands and 
receptors were docked using a grid spacing of 0.375 and 60 x 60 x 60 number of grid points. 
Through Lamarckian 4.2 method, each ligand was docked in autodock vina for 3 times, which 
generated total 60 possible conformations. To analyze the results, Chimera was initially used 
to view the binding energy, in combination with analysis and validation of possible interactions 
in LigPlus.  
In vitro antituberculosis activity 
The MIC values of all compounds were determined as previously decribed [51,52]. In brief, M. 
tuberculosis H37Rv (ATCC 27294) was grown to OD650nm 0.2 in the respective medium prior to 
further 1000-fold dilution in fresh medium. Drugs were 2-fold serially diluted in duplicate in the 
medium of choice (50 L/well) in a concentration range spanning 100-0.049 M in sterile 96-
well U-bottom clear polysteyrene microtiter plates. Isoniazid and DMSO as postive and negative 
controls, respectively. An equal volume (50 L) of diluted cells was added to the plates with the 
serial drug dilution. Plates were sealed in ziplock bags and incubated at 37 ℃. After 7-14 days, 
plates were read with enlarging inverted mirror plate reader. The MIC was recorded as the 
concentration that fully inhibited all visible growth. 
In vitro cytotoxicity assay  
The cytotoxicity of compounds on MRC-5 fibroblasts was performed exactly as previously 
reported [12].  
Stability assay 
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Preparation of pH 6.6 bicarbonate-formic acid buffer: 158.12 mg ammonium bicarbonate was 
dissolved in 10 ml H2O to prepara 0.2 M ammonium bicarbonate. 0.2 M formic acid solution 
was prepared by dissolving 150.8 ul formic acid in 20 ml H2O. To obtain ammonium pH 6.6 
bicarbonate-formic acid buffer, 10 ml 0.2 M ammonium bicarbonate solution was titrated with 
0.2 M formic acid solution under monitoration of pH meter. Preparation of sample: the tested 
compound was solubilized in DMSO (Sigma - Aldrich) at stock concentration of 8 mM. Serial 
dilutions were made in bicarbonate-formic acid buffer. Volumes of 20 μL of the serial dilutions 
were injected into LC-MS system to build the standard curve. Volumes of 3 mL solutions at 
concentration 80 μM were used as working solution. Volumes of 20 μL of the working solutions 
were measured with LC-MC at time piont 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h. Area of the 
curve was collected and analysed by excel and MatLab. 
Chemistry 
Regeants were purchased and used without any further purification. All synthetic compounds 
presented in this study were checked with precoated Alugram Silica TLC F254 plates 
(Machhery-Nagel), visualized under UV light at 254 nm or stained by potassium permanganate, 
and purified by column chromatography on a Reveleris X2 (Grace) automated flash unit. 1H 
and 13C NMR spectral data were obtained on a Varian Mercury 300/75 MHz spectrometer at 
300 K using TMS as an internal standard. Structural assignment was confirmed with the 
assistance of 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC. High resolution mass 
spectrometry (HRMS) was performed at 1ng/ml on a Waters LCT Premier XETM time of flight 
(TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and modular 
LockSprayTM interface, using 0.1% HCOOH in MeCN/H2O (1:1) as mobile phase. Purity of final 
compounds was determined by LC-MS analysis on a Phenomenex Kinetex EVO C18 5 μm 100 
mm × 2.1 mm column at flow rate of 1.4 mL/min (Waters Alliance 2695 XE separation module), 
using HCOOH in H2O (0.1%, v/v)/ MeCN as gradient system.  
General procedure 1: synthsis of 3-((benzyloxy)methyl)-5-methy-1-(1-(substituted 
quinolin-2-ylmethyl)-4-yl)pyrimidine-2,4(1H,3H)-dione.  
Method A To a solution of substituted quinoline buiding blocks (1.0 eq.) in dioxane was added 
selenium dioxide (1.3 eq). The resulting mixture was refluxed overnight. Then, the reaction 
mixture was cooled to room temperature and appropriate volume of EA was added for dilution, 
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followed by filtration through celite. The collected filtrate was extracted with water and the 
organic phase was dried and concentrated in vacuo. The resulting residue and 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione [11] (5, 0.67 eq.) 
were dissolved in 1,2-dichloroethane under N2 and the mixture was stirred for 0.5 h, followed 
by addition of sodium triacetoxyborohydride (2.0 eq.). After stirring overnight, the reaction 
mixture was diluted with CH2Cl2, washed with sat. NaHCO3 and brine, and dried over Na2SO4. 
The combined organic layers were filtered, concentrated and purified by silica chromatography 
to give the title compound. 
Method B To a solution of substituted quinoline buiding blocks (1.0 eq.) in CCl4 were added N-
bromosuccinimide (0.9 eq.) and 2,2-azobisisobutyronitrile (0.2 eq.). The resulting mixture was 
refluxed overnight. Then the reaction mixture was cooled to room temperature and filtered to 
remove the solid. After being extracted with sat. NaHCO3 and brine, the organic layer was dried 
and concentrated. The resulting residue, 5 (1.0 eq.) and K2CO3 (3 eq.) were dissolved in ethanol 
and the mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature and 
filtered. The concentrated filtrate was purified by silica chromatography to give the title 
compound. 
General procedure 2: synthesis of 5-methyl-1-(1-(4-substituted quinolin-2-
ylmethyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 
To a solution of 3-((benzyloxy)methyl)-1-(1-((substituted 4-chloroquinolin-2-yl)methyl)piperidin-
4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (1.0 eq.) in EA (2.0 mL) was added the phenol 
derivatives (1.5 eq.) and the resulting mixture was heated at 180 ℃ for 0.5 h. After cooled to 
room temperature, the reaction mixture was purified by silica chromatography to give BOM-
protected intermediate, which was heated at 73 ℃ in TFA to yield the title compound after 
purification. 
3-((Benzyloxy)methyl)-1-(1-((4-chloroquinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (3) Following method A in General procedure 1, 4-chloro-2-methyl quinoline 
(0.20 g, 1.1 mmol) and selenium dioxide (0.16 g, 1.5 mmol) in dioxane (20 mL) afforded the 
aldehyde intermediate, which was dissolved in 1,2-dichloroethane together with 5 (0.25 g, 0.75 
mmol) synthesized according to previously reported procedure [11], followed by addition of 
sodium triacrtoxyborohydride (0.48 g, 2.3 mmol) to yield 3 (eluent system: 55% EA in petroleum 
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ether, 0.18 g, 32%). 1H NMR (300 MHz, CDCl3) δ ppm 1.77 - 1.96 (m, 7 H, 5-CH3, piperidin-3-
yl, piperidin-5-yl), 2.27 - 2.40 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 3.02 (d, J = 12.0 Hz, 2 H, 
piperidin-2b-yl, piperidin-6b-yl), 3.81 (s, 2 H, NpiperidylCH2), 4.47 - 4.62 (m, 1 H, piperidin-4-yl), 
4.70 (s, 2 H, (Ph)CH2), 5.50 (s, 2 H, N3CH2), 7.06 (d, J = 1.2 Hz, 1 H, H-6), 7.17 - 7.40 (m, 5 H, 
Ph, quinolin-3-yl), 7.60 (ddd, J = 8.3, 7.0, 1.2 Hz, 1 H, Ph), 7.68 - 7.80 (m, 2 H, Ph), 8.06 (dd, J 
= 8.5, 0.6 Hz, 1 H, Ph), 8.19 (dd, J = 8.4, 1.3 Hz, 1 H, Ph). 13C NMR (75 MHz, DMSO-d6) δ ppm 
13.16 (1 C, 5-CH3), 30.72 (2 C, piperidin-3-yl, piperidin-5-yl), 52.96 (2 C, piperidin-2-yl, 
piperidin-6-yl), 53.13 (1 C, piperidin-4-yl), 64.28 (1 C, NpiperidylCH2), 70.73 (1 C, N3CH2), 72.12 
(1 C, (Ph)CH2), 109.93 (1 C, C-5), 120.69 (1 C, quinolin-3-yl), 123.85 (1 C, Ph), 125.47 (1 C, 
Ph), 127.15 (1 C, Ph), 217.44 (1 C, Ph), 127.47 (2 C, Ph), 128.11 (2 C, Ph), 129.28 (1 C, Ph), 
130.31 (1 C, Ph), 134.88 (1 C, C-6), 137.96 (1 C, Ph), 142.93 (1 C, quinolin-4-yl), 148.33 (1 C, 
Ph), 151.42 (1 C, C-2), 159.37 (1 C, quibolin-2-yl), 163.12 (1 C, C-4). HRMS (ESI): m/z [M + 
H]+ Calcd. for [C28H29ClN4O3 + H]+ 505.2001, found 505.1318. 
5-Methyl-1-(1-((4-oxo-1,4-dihydroquinolin-2-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-
dione (4) To a 25 mL flask were added 3 (0.10 g, 0.20 mmol) in acetic acid (10 mL) and the 
mixture was heated at 125 ℃ for 2 h. After total consumption of 3 checked with TLC, solvent 
was removed in vacuo. The resulting residue was dissolved in TFA (5.0 mL) and heated at 73 ℃ 
for 4 h, followed by removing the volatile composition, adjusting the pH to 6-7 with sat. NaHCO3 
and the concentrated residue was purified with silica chromatography to give 4 (eluent system: 
5% methanol in CH2Cl2, 42 mg, 58%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.61-1.72 (m, 2 H, 
piperidin-3a-yl, piperidin-5a-yl), 1.76 (s, 3 H, 5-CH3), 1.81 - 2.01 (m, 2 H, piperidin-3b-yl, 
piperidin-5b-yl), 2.20 (t, J = 11.0 Hz, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.97 (d, J = 11.1 Hz, 
2 H, piperidin-2b-yl, piperidin-6b-yl), 3.50 (s, 2 H, NpiperidylCH2), 4.20 - 4.33 (m, 1 H, piperidin-4-
yl), 6.07 (s, 1 H, quinolin-3-yl), 7.26 (dt, J = 7.8, 4.1 Hz, 1 H, Ph), 7.50 - 7.67 (m, 3 H, H-6, Ph), 
8.03 (d, J = 8.2 Hz, 1 H, Ph), 11.19 (br. s., 1 H, ), 11.41 (br. s., 1 H). 13C NMR (75 MHz, DMSO-
d6) δ ppm 11.74 (1 C, 5-CH3), 29.51 (2 C, piperidin-3-yl, piperidin-5-yl), 52.03 (1 C, piperidin-4-
yl), 52.21 (2 C, piperidin-2-yl, piperidin-6-yl), 58.64 (1 C, NpiperidylCH2), 107.85 (1 C, quinolin-3-
yl), 108.66 (1 C, C-5), 117.91 (1 C, Ph), 122.57 (1 C, Ph), 124.49 (1 C, Ph), 124.70 (1 C, Ph), 
131.24 (1 C, Ph), 137.33 (1 C, Ph), 139.85 (1 C, C-6), 149.57 (1 C, quinolin-2-yl), 150.52 (1 C, 
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C-2), 163.38 (1 C, C-4), 176.60 (1 C, quinolin-4-yl). HRMS (ESI): m/z [M + H]+ Calcd. for 
[C20H22N4O3 + H]+ 367.1765, found 367.1714. 
2-Hydroxy-4-((2-((4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)methyl)quinolin-4-yl)oxy)benzoic acid (6) Following General procedure 2, 3 (0.20 g, 0.40 
mmol) and 2,4-dihydroxybenzoic acid (92 mg, 0.60 mmol) in EA (2.0 mL) afforded the protected 
intermediate, which was heated in TFA (5.0 mL) at 73 ℃ for 4 h to yield 6 (eluent system: 10% 
methanol in CH2Cl2, 76 mg, 38%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.76 (s, 3 H, 5-CH3), 
1.80 - 1.97 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 2.01 - 2.27 (m, 2 H, piperidin-3b-yl, 
piperidin-5b-yl), 2.97 - 3.15 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 3.43 (d, J = 11.4 Hz, 2 H, 
piperidin-2b-yl, piperidin-6b-yl), 4.24 - 4.60 (m, 3 H, piperidin-4-yl, NpiperidylCH2), 6.62 - 6.76 (m, 
2 H, H-6, Ph), 7.09 (s, 1 H, quinolin-3-yl), 7.46 (s, 1 H, Ph), 7.68 (t, J = 7.6 Hz, 1 H, Ph), 7.79 - 
7.92 (m, 2 H, Ph), 8.07 (d, J = 8.5 Hz, 1 H, Ph), 8.24 (d, J = 7.9 Hz, 1 H, Ph), 11.26 (s, 1 H, NH). 
13C NMR (75 MHz, DMSO-d6) δ ppm 12.14 (1 C, 5-CH3), 26.95 (2 C, piperidin-3-yl, piperidin-
5-yl), 50.09 (1 C, piperidin-4-yl), 51.52 (2 C, piperidin-2-yl, piperidin-2-yl), 59.81 (1 C, 
NpiperidylCH2), 106.02 (1 C, quinolin-3-yl), 107.90 (1 C, Ph), 109.25 (1 C, Ph), 110.05 (1 C, C-5), 
115.30 (1 C, Ph), 120.32 (1 C, Ph), 121.57 (1 C, Ph), 127.10 (1 C, Ph), 128.60 (1 C, Ph), 130.98 
(1 C, Ph), 132.38 (1 C, Ph), 137.14 (1 C, C-6), 148.52 (1 C, Ph), 150.71 (1 C, C-2), 154.61 (1 
C, quinolin-2-yl), 158.15 (t, J = 31.5 Hz, 1 C, Ph) , 160.64 (1 C, quinolin-4-yl), 163.61 (1 C, C-
4), 163.77 (1 C, C-OH), 171.37 (1 C, COOH). HRMS (ESI): m/z [M + H]+ Calcd. for [C27H26N4O6 
+ H]+ 503.1925, found 503.1951. 
1-(1-((4-(4-Hydroxyphenoxy)quinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (7) Following General procedure 2, 3 (0.40 g, 0.79 mmol) and hydroquinone 
(0.30 g, 2.7 mmol) in EA (2.0 mL) afforded the protected intermediate, which was heated in TFA 
(5.0 mL) at 73 ℃ for 4 h to yield 7 (eluent system: 5% methanol in CH2Cl2, 0.17 g, 46%). 1H 
NMR (300 MHz, DMSO-d6) δ ppm 1.46 - 1.86 (m, 7 H, 5-CH3, piperidin-3-yl, piperidin-5-yl), 
2.08 (t, J = 10.7 Hz, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.78 - 2.88 (m, 2 H, piperidin-2b-yl, 
piperidin-6b-yl), 3.61 (s, 2 H, NpiperidylCH2), 4.14 - 4.26 (m, 1 H, piperidin-4-yl), 6.67 (s, 1 H, 
quinolin-3-yl), 6.87 (d, J = 9.1 Hz, 2 H, Ph), 7.08 (d, J = 8.8 Hz, 2 H, Ph), 7.47 (s, 1 H, H-6), 
7.53 - 7.61 (m, 1 H, Ph), 7.71 - 7.80 (m, 1 H, Ph), 7.93 (d, J = 8.5 Hz, 1 H, Ph), 8.23 (d, J = 7.9 
Hz, 1 H, Ph), 9.66 (br.s., 1 H, OH), 11.12 (br.s., 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 
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11.82 (1 C, 5-CH3), 29.63 (2 C, piperidin-3-yl, piperidin-5-yl), 52.10 (1 C, piperidin-4-yl), 52.32 
(2 C, piperidin-2-yl, piperidin-6-yl), 63.84 (1 C, NpiperidylCH2), 102.66 (1 C, quinolin-3-yl), 108.77 
(1 C, C-5), 116.38 (2 C, Ph), 119.71 (1 C, Ph), 121.15 (1 C, Ph), 121.80 (2 C, Ph), 125.68 (1 C, 
Ph), 128.15 (1 C, Ph), 130.00 (1 C, Ph), 137.25 (1 C, C-6), 145.56 (1 C, Ph), 148.23 (1 C, Ph), 
150.56 (1 C, C-2), 154.87 (1 C, Ph), 160.38 (1 C, quinolin-2-yl), 161.90 (1 C, quinolin-4-yl), 
163.48 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C26H26N4O4 + H]+ 459.2027, found 
459.2043. 
4-((2-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)quinolin-4-
yl)oxy)benzoic acid (8) Following General procedure 2, 3 (0.45 g, 0.89 mmol) and methyl 4-
hydroxybenzoate (0.20 g, 1.3 mmol) in EA (2.0 mL) afforded the protected intermediate, which 
was hydrolysis in 2 N aq. NaOH solution (20 mL) at 50 ℃ for 4h, and acidified with 2 M aq. HCl 
(25 mL) to give the acid intermediate. The resulting residue was heated in TFA (5.0 mL) at 73 ℃ 
for 4 h to yield 8 (eluent system: 10% methanol in CH2Cl2, 0.18 g, 41%). 1H NMR (300 MHz, 
DMSO-d6) δ ppm 1.77 (s, 3 H, 5-CH3), 1.87 - 1.95 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 2.23 
- 2.32 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 3.21 - 3.28 (m, 2 H, piperidin-2a-yl, piperidin-6a-
yl), 3.55 - 3.62 (m, 2 H, piperidin-2b-yl, piperidin-6b-yl), 4.49 - 4.66 (m, 3 H, NpiperidylCH2, 
piperidin-4-yl), 7.04 (s, 1 H, quinolin-3-yl), 7.43 (d, J = 8.8 Hz, 3 H, H-6, Ph), 7.68 - 7.77 (m, 1 
H, Ph), 7.85 - 7.96 (m, 1 H, Ph), 8.08 (d, J = 8.8 Hz, 3 H, Ph), 8.30 (d, J = 8.8 Hz ,1 H, Ph), 
11.29 (s, 1 H, NH), H (COOH) could not be observed. 13C NMR (75 MHz, DMSO-d6) δ ppm 
12.22 (1 C, 5-CH3), 26.17 (2 C, piperidin-3-yl, piperidin-5-yl), 49.68 (1 C, piperidin-4-yl), 51.26 
(2 C, piperidin-2-yl, piperidin-6-yl), 59.75 (1 C, NpiperidylCH2), 106.25 (1 C, quinolin-3-yl), 109.35 
(1 C, C-5), 120.32 (1 C, Ph), 120.55 (3 C, Ph), 121.63 (1 C, Ph), 127.44 (1 C, Ph), 128.09 (1 C, 
Ph), 128.61 (1 C, Ph), 131.27 (1 C, Ph), 131.98 (2 C, Ph), 137.05 (1 C, C-6), 150.68 (1 C, C-
2), 157.55 (1 C, Ph), 160.60 (1 C, quinolin-4-yl), 163.60 (1 C, C-4), 166.56 (1 C, COOH), C 
(quinolin-2-yl) could not be observed. HRMS (ESI): m/z [M + H]+ Calcd. for [C27H26N4O5 + H]+ 
487.1976, found 487.2204. 
1-(1-((4-(2-Hydroxyethoxy)quinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione (9) Following General procedure 2, 3 (0.20 g, 0.40 mmol) and ethylene glycol (37 mg, 
0.60 mmol) in EA (2.0 mL) afforded the protected intermediate, which was heated in TFA (5.0 
mL) at 73 ℃ for 4 h to yield 9 (eluent system: 10% methanol in CH2Cl2, 66 mg, 41%). 1H NMR 
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(300 MHz, DMSO-d6) δ ppm 1.79 (s, 3 H, 5-CH3), 1.85 - 2.01 (m, 2 H, piperidin-3a-yl, piperidin-
5a-yl), 2.16 - 2.36 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 3.18 - 3.30 (m, 2 H, piperidin-2a-yl, 
piperidin-6a-yl), 3.5 - 3.67 (m, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.88 (t, J = 4.7 Hz, 2 H, 
OCH2), 4.29 (t, J = 4.7 Hz, 2 H, OCH2), 4.45 - 4.71 (m, 3 H, piperidin-4-yl, NpiperidylCH2), 7.18 (s, 
1 H, quinolin-3-yl), 7.46 (s, 1 H, H-6), 7.62 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 H, Ph), 7.81 (ddd, J = 
8.4, 7.0, 1.3 Hz, 1 H, Ph), 8.00 (d, J = 8.2 Hz, 1 H, Ph), 8.26 (dd, J = 8.5, 0.9 Hz, 1 H, Ph), 
11.30 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.67 (1 C, 5-CH3), 26.99 (2 C, 
piperidin-3-yl, piperidin-5-yl), 50.42 (1 C, piperidin-4-yl), 52.03 (2 C, piperidin-2-yl, piperidin-6-
yl), 59.65 (2 C, CH2OH, NpiperidylCH2), 71.25 (1 C, OCH2), 102.01 (1 C, quinolin-3-yl), 109.77 (1 
C, C-5), 120.65 (1 C, Ph), 122.51 (1 C, Ph), 126.79 (1 C, Ph), 128.42 (1 C, Ph), 131.12 (1 C, 
Ph), 137.61 (1 C, C-6), 147.99 (1 C, Ph), 151.16 (1 C, C-2), 162.64 (1 C, quinolin-4-yl), 164.08 
(1 C, C-4), C (quinolin-2-yl) could not be observed. HRMS (ESI): m/z [M + H]+ Calcd. for 
[C22H26N4O4 + H]+ 411.2027, found 411.2037. 
1-(1-((4-((2-Hydroxyethyl)amino)quinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (10) Following General procedure 2, 3 (0.20 g, 0.40 mmol) and ethanolamine 
(36 mg, 0.60 mmol) in EA (2.0 mL) afforded the protected intermediate, which was heated in 
TFA (5.0 mL) at 73 ℃ for 4 h to yield 10 (eluent system: 10% methanol in CH2Cl2, 55 mg, 34%). 
1H NMR (300 MHz, DMSO-d6) δ ppm 1.57 - 1.83 (m, 5 H, 5-CH3, piperidin-3a-yl, piperidin-5a-
yl), 1.87 - 2.06 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 2.32 - 2.44 (m, 2 H, piperidin-2a-yl, 
piperidin-6a-yl), 3.07 (d, J = 11.1 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.58 - 3.66 (m, 2 H, 
NCH2), 3.71 (t, J = 5.6 Hz, 2 H, OCH2), 3.91 (br. s., 2 H, NpiperidylCH2), 4.23 - 4.41 (m, 1 H, 
piperidin-4-yl), 6.93 (s, 1 H, quinolin-3-yl), 7.55 (s, 1 H, H-6), 7.61 - 7.73 (m, 1 H, Ph), 7.84 - 
8.03 (m, 2 H, Ph), 8.48 (d, J = 8.5 Hz, 1 H, Ph), 9.17 (t, J = 6.2 Hz, 1 H, (Ph)NH), 11.22 (s, 1 H, 
NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.37 (1 C, 5-CH3), 29.60 (2 C, piperidin-3-yl, 
piperidin-5-yl), 46.10 (1 C, NCH2), 52.32 (1 C, piperidin-4-yl), 52.59 (2 C, piperidin-2-yl, 
piperidin-6-yl), 58.47 (1 C, NpiperidylCH2), 59.06 (1 C, CH2OH), 98.68 (1 C, quinolin-3-yl), 109.27 
(1 C, C-5), 116.52 (1 C, Ph), 120.54 (1 C, Ph), 123.28 (1 C, Ph), 126.54 (1 C, Ph), 133.63 (1 C, 
Ph), 137.79 (1 C, C-6), 138.55 (1 C, Ph), 151.07 (1 C, C-2), 156.04 (1 C, quinolin-4-yl), 158.44 
(1 C, quinolin-2-yl), 163.93 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C22H27N5O3 + H]+ 
410.2187, found 410.2199. 
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3-((Benzyloxy)methyl)-1-(1-((8-hydroxyquinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (12) Following method B in General procedure 1, 2-methylquinolin-8-yl 
acetate (0.55 g, 2.7 mmol), N-bromosuccinimide (0.44 g, 2.5 mmol) and 2,2-
azobisisobutyronitrile (90 mg, 0.55 mmol) were refluxed in CCl4 (25 mL) to give the bromo 
substituted intermediate, which was further treated with 5 (0.90 g, 2.7 mmol) and K2CO3 (1.1 g, 
8.2 mmol) in ethanol to afford 12 (eluent system: 55% EA in petroleum ether, 0.25 g, 20%). 1H 
NMR (300 MHz, CDCl3) δ ppm 1.85 - 2.00 (m, 7 H, 5-CH3, piperidin-3-yl, piperidin-5-yl), 2.21 - 
2.39 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 3.06 (d, J = 11.7 Hz, 2 H, piperidin-2b-yl, piperidin-
6b-yl), 3.82 - 3.88 (m, 2 H, NpiperidylCH2), 4.48 - 4.64 (m, 1 H, piperidin-4-yl), 4.69 (s, 2 H, 
(Ph)CH2), 5.49 - 5.51 (m, 2 H, N3CH2), 7.09 (d, J = 0.9 Hz, 1 H, H-6), 7.15 (dd, J = 7.5, 1.3 Hz, 
1 H, quinolin-3-yl), 7.19 - 7.32 (m, 4 H, Ph), 7.33 - 7.45 (m, 3 H, Ph), 7.52 (d, J = 8.2 Hz, 1 H, 
Ph), 8.11 (d, J = 8.5 Hz, 1 H, Ph). 13C NMR (75 MHz, CDCl3) δ ppm 13.15 (1 C, 5-CH3), 29.92 
(2 C, piperidin-3-yl, piperidin-5-yl), 52.82 (2 C, piperidin-2-yl, piperidin-6-yl), 53.14 (1 C, 
piperidin-4-yl), 63.53 (1 C, NpiperidylCH2), 70.80 (1 C, N3CH2), 72.16 (1 C, (Ph)CH2), 110.16 (1 C, 
C-5), 110.38 (1 C, Ph), 117.50 (1 C, Ph), 121.47 (1 C, quinolin-3-yl), 127.51 (4 C, Ph), 127.62 
(1 C, Ph), 128.15 (2 C, Ph), 134.43 (1 C, C-6), 135.01 (1 C, quinolin-4-yl), 136.70 (1 C, Ph), 
137.97 (1 C, Ph), 151.46 (1 C, C-2), 152.15 (1 C, C-OH), 163.17 (1 C, C-4), 168.89 (1 C, 
quinolin-2-yl). HRMS (ESI): m/z [M + H]+ Calcd. for [C28H30N4O4 + H]+ 487.2340, found 487.2344. 
1-(1-((8-Hydroxyquinolin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (13) 
A solution of 12 (0.20 g, 0.41 mmol) in TFA (4.0 mL) was heated at 73 ℃ for 4 h to yield 13 
(eluent system: 5% methanol in CH2Cl2, 87 mg, 58%). 1H NMR (300 MHz, DMSO-d6) ppm δ 
1.62 - 1.71 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 1.76 (s, 3 H, 5-CH3), 1.82 - 1.99 (m, 2 H, 
piperidin-3b-yl, piperidin-5b-yl), 2.14 - 2.27 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.95 (d, J 
= 12.0 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.81 (s, 2 H, NpiperidylCH2), 4.22 - 4.37 (m, 1 H, 
piperidin-4-yl), 7.06 (dd, J = 6.7, 2.3 Hz, 1 H, Ph), 7.31 - 7.42 (m, 2 H, Ph), 7.61 - 7.69 (m, 2 H, 
H-6, quinolin-3-yl), 8.27 (d, J = 8.8 Hz, 1 H, quinolin-4-yl), 9.48 (s, 1 H, OH), 11.18 (s, 1 H, NH). 
13C NMR (75 MHz, DMSO-d6) δ ppm 12.00 (1 C, 5-CH3), 30.08 (2 C, piperidin-3-yl, piperidin-
5-yl), 52.27 (1 C, piperidin-4-yl), 52.75 (2 C, piperidin-2-yl, piperidin-6-yl), 63.86 (1 C, 
NpiperidylCH2), 108.95 (1 C, C-5), 111.25 (1 C, Ph), 117.59 (1 C, Ph), 121.33 (1 C, quinolin-3-yl), 
126.96 (1 C, Ph), 127.80 (1 C, Ph), 136.35 (1 C, Ph), 137.69 (1 C, C-6), 150.82 (1 C, C-2), 
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152.84 (1 C, C-OH), 157.55 (2 C, quinolin-2-yl, quinolin-4-yl), 163.67 (1 C, C-4). HRMS (ESI): 
m/z [M + H]+ Calcd. for [C20H22N4O3 + H]+ 367.1765, found 367.1778. 
[2,2'-Bipyridine]-6-carbaldehyde (15) According to a literature procedure [53], a solution of 6-
bromo-2-pyridinecarboxaldehyde (0.20 g, 1.1 mmol), 2-(tributylstannyl)pyridine (0.37 g, 1.0 
mmol) and tetrakis(triphenylphosphine)palladium (41 mg, 0.035 mmol) in degased tolune (20 
mL) was refluxed overnight under nitrogen. The volatile in the resulting brown mixture was 
removed in vacuo. The crude aldehyde was purified by column chromatography to afford 15 
(eluent system: 25% EA in petroleum, 74 mg, 40%). 1H NMR (300 MHz, CDCl3) δ ppm 7.30 - 
7.39 (m, 1 H, Py), 7.80 - 7.88 (m, 1 H, Py), 7.91 - 7.98 (m, 2 H, Py), 8.49 - 8.55 (m, 1 H, Py), 
8.59 - 8.65 (m, 1 H, Py), 8.66 - 8.71 (m, 1 H, Py), 10.15 (s, 1 H, CHO). 13C NMR (75 MHz, 
CDCl3) δ ppm 121.18 (1 C, Py), 121.30 (1 C, Py), 124.23 (1 C, Py), 125.05 (1 C, Py), 136.99 
(1 C, Py), 137.83 (1 C, Py), 149.22 (1 C, Py), 152.20 (1 C, Py), 154.85 (1 C, Py), 156.55 (1 C, 
Py), 193.56 (1 C, CHO). HRMS (ESI): m/z [M + H]+ Calcd. for [C11H8N2O + H]+ 185.0710, found 
185.0696. 
[2,2'-Bipyridin]-6-ylmethanol (16) To a solution of 15 (0.10 g, 0.54 mmol) in 1,2-dichloroethane 
was added sodium triacetylborohydride (0.23 g, 1.1 mmol) and the resulting mixture was stirred 
at room temperature overnight. After completion of starting material checked with TLC, the 
mixture was washed with sat. NaHCO3 (25 mL), brine (25 mL) and dried with Na2SO4. The 
crude alcohol was concentrated and purified by column chromatography to afford pure 16 
(eluent system: 50% EA in petroleum, 50 mg, 49%). 1H NMR (300 MHz, CDCl3) δ ppm 4.54 (br. 
s., 1 H, OH), 4.78 (s, 2 H, CH2), 7.18 - 7.29 (m, 2 H, Py), 7.66 - 7.78 (m, 2 H, Py), 8.21 (d, J = 
7.9 Hz, 1 H, Py), 8.27 - 8.34 (m, 1 H, Py), 8.57 - 8.65 (m, 1 H, Py). 13C NMR (75 MHz, CDCl3) 
δ ppm 64.12 (1 C, CH2), 119.48 (1 C, Py), 120.32 (1 C, Py), 120.96 (1 C, Py), 123.65 (1 C, Py), 
136.79 (1 C, Py), 137.45 (1 C, Py), 148.99 (1 C, Py), 154.62 (1 C, Py), 155.51 (1 C, Py), 158.65 
(1 C, Py). HRMS (ESI): m/z [M + H]+ Calcd. for [C11H10N2O + H]+ 187.0866, found 187.0855. 
1-(1-([2,2'-Bipyridin]-6-ylmethyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (17) To a 
solution of 16 (50 mg, 0.27 mmol) in CH2Cl2 were added methanesulfonyl chloride (25 μl, 0.32 
mmol) and triethylamine (58 μl, 0.42 mmol) and the resulting solution was stirred at room 
temperature for 1 h. The reaction mixture was washed with 1 M aq. HCl (25 mL), sat. NaHCO3 
(25 mL) and brine (25 mL), and dried over Na2SO4. The concentrated residue, 5 (0.11 g, 0.34 
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mmol) and K2CO3 (63 mg, 0.46 mmol) were dissolved in ethanol (20 mL) and the solution was 
refluxed for 2 h. The reaction mixture was concentrated in vacuo, and the residue was washed 
with 1 M aq. HCl (25 mL), sat. NaHCO3 (25 mL) and brine (25 mL), and dried over Na2SO4. 
After solvent evaporation in vacuo, the BOM protected intermediate was treated with TFA (4.0 
mL) at 73 ℃ for 4 h to yield 17 (eluent system: 7% methanol in CH2Cl2, 26 mg, 26%). 1H NMR 
(300 MHz, DMSO-d6) δ ppm 1.60 - 1.71 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 1.75 (s, 3 H, 
5-CH3), 1.88 (qd, J = 12.1, 3.4 Hz, 2 H, piperidin-3b-yl, piperidin-5b-yl), 2.19 (t, J = 10.8 Hz, 2 
H, piperidin-2a-yl, piperidin-6a-yl), 2.98 (d, J = 11.7 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 
3.71 (s, 2 H, NpiperidylCH2), 4.20 - 4.34 (m, 1 H, piperidin-4-yl), 7.42 (ddd, J = 7.6, 4.7, 1.2 Hz, 1 
H, Py), 7.50 (dd, J = 7.8, 1.0 Hz, 1 H, Py), 7.64 (d, J = 1.2 Hz, 1 H, H-6), 7.86 - 7.97 (m, 2 H, 
Py), 8.25 (dd, J = 7.9, 0.9 Hz, 1 H, Py), 8.36 (dt, J = 8.0, 1.1 Hz, 1 H, Py), 8.62 - 8.68 (m, 1 H, 
Py), 11.17 (br. s., 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.3 (1 C, 5-CH3), 30.3 (2 C, 
piperidin-3-yl, piperidin-5-yl), 52.6 (1 C, piperidin-4-yl), 52.9 (2 C, piperidin-2-yl, piperidin-6-yl), 
63.8 (1 C, NpiperidylCH2), 109.2 (1 C, C-5), 119.0 (1 C, Py), 120.7 (1 C, Py), 123.3 (1 C, Py), 
124.4 (1 C, Py), 137.5 (1 C, Py), 137.9 (1 C, Py), 138.0 (1 C, C-6), 149.5 (1 C, Py), 151.1 (1 C, 
C-2), 154.8 (1 C, Py), 155.5 (1 C, Py), 158.7 (1 C, Py), 164.0 (1 C, C-4). HRMS (ESI): m/z [M 
+ H]+ Calcd. for [C21H23N5O2 + H]+ 378.1925, found 378.1385. 
2-((2-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)quinolin-4-
yl)oxy)ethyl 3,4-dihydroxybenzoate (18) 3,4-Bis(benzyloxy)benzoyl chloride was synthesized 
according to the literature [54]. To a solution of 9 (0.10 g, 0.24 mmol) and 4-
methylatemorpholine (32 μl, 0.29 mmol) in CH2Cl2 (10 mL) was added 3,4-
bis(benzyloxy)benzoyl chloride (90 mg, 0.26 mmol) and the resulting solution was stirred for 1 
h. The reaction mixture was quenched with water and washed with 1 M aq. HCl (25 mL), sat. 
NaHCO3 (25 mL) and brine (25 mL), dried with Na2SO4, followed by concentration to give the 
intermediate. The BOM protected intermediated and Pd/C were dissolved in ethanol (10 mL) 
and the mixture was stirred at room temperature under a hydrogen balloon overnight to give 18 
(eluent system: 7% methanol in CH2Cl2, 28 mg, 21%). 1H NMR (300 MHz, METHANOL-d4) δ 
ppm 1.89 (s, 3 H, 5-CH3), 1.97 - 2.10 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 2.25 - 2.47 (m, 2 
H, piperidin-3b-yl, piperidin-5b-yl), 3.11 (t, J = 11.9 Hz, 2 H, piperidin-2a-yl, piperidin-6a-yl), 
3.54 - 3.68 (m, 2 H, piperidin-2b-yl, piperidin-6b-yl), 4.43 (br. s., 2 H, NpiperidylCH2), 4.53 - 4.64 
 26 
(m, 1 H, piperidin-4-yl), 4.68 (br. s., 2 H, OCH2), 4.79 (s, 2 H, OCH2), 6.76 (d, J = 8.2 Hz, 1 H, 
Ph), 7.19 (s, 1 H, quinolin-3-yl), 7.35 - 7.44 (m, 2 H, Ph), 7.49 (s, 1 H, H-6), 7.59 (t, J = 8.2 Hz, 
1 H, Ph), 7.79 (t, J = 7.6 Hz, 1 H, Ph), 8.02 (d, J = 8.5 Hz, 1 H, Ph), 8.24 (d, J = 8.2 Hz, 1 H, 
Ph). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.49 (1 C, 5-CH3), 27.07 (2 C, piperidin-3-yl, 
piperidin-5-yl), 50.65 (1 C, piperidin-4-yl), 52.01 (2 C, piperidin-2-yl, piperidin-6-yl), 62.45 (2 C, 
NpiperidylCH2, OCH2), 67.54 (1 C, OCH2), 101.99 (1 C, quinolin-3-yl), 109.62 (1 C, C-5), 115.64 
(1 C, Ph), 116.66 (1 C, Ph), 120.34 (1 C, Ph), 120.54 (1 C, Ph), 121.88 (1 C, Ph), 122.23 (1 C, 
Ph), 126.81 (1 C, Ph), 128.50 (1 C, Ph), 130.92 (1 C, Ph), 137.53 (1 C, C-6), 145.42 (1 C, Ph), 
147.98 (1 C, Ph), 150.97 (1 C, Ph), 151.05 (1 C, C-2), 161.84 (1 C, quinolin-4-yl), 163.98 (1 C, 
C-4), 165.96 (1 C, CO(Ph)), C(quinolin-2-yl) could not be observed. HRMS (ESI): m/z [M + H]+ 
Calcd. for [C29H30N4O7 + H]+ 547.2187, found 547.2191. 
2-((2-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)quinolin-4-
yl)amino)ethyl 3,4-dihydroxybenzoate (19) Following the same procedure as decribed for 18, 
using 10 (0.10 g, 0.24 mmol), 4-methylatemorpholine (32 μl, 0.29 mmol) and 3,4-
bis(benzyloxy)benzoyl chloride (90 mg, 0.26 mmol) as material yielded the intermediate. The 
BOM protected intermediated and Pd/C were dissolved in ethanol (10 mL) and the resulting 
solution was stirred at room temperature under a hydrogen balloon overnight to give 19 (eluent 
system: 7% methanol in CH2Cl2, 29 mg, 21%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.59 - 1.70 
(m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 1.74 (s, 3 H, 5-CH3), 1.82 - 2.01 (m, 2 H, piperidin-3b-
yl, piperidin-5b-yl), 2.16 - 2.30 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.97 (d, J = 11.4 Hz, 2 
H, piperidin-2b-yl, piperidin-6b-yl), 3.69 (br. s., 2 H, NpiperidylCH2), 3.74 - 3.86 (m, 2 H, NCH2), 
4.20 - 4.34 (m, 1 H, piperidin-4-yl), 4.47 (t, J = 5.0 Hz, 2 H, OCH2), 6.76 (d, J = 8.2 Hz, 1 H, Ph), 
6.84 (s, 1 H, quinolin-3-yl), 7.22 - 7.35 (m, 2 H, Ph), 7.47 - 7.59 (m, 2 H, H-6, Ph), 7.72 (t, J = 
6.7 Hz, 1 H, Ph), 7.88 (d, J = 8.8 Hz, 1 H, Ph), 8.31 (d, J = 7.9 Hz, 1 H，Ph), 9.32 (s, 1 H, NH), 
9.85 (s, 2 H, OH), 11.20 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.38 (1 C, 5-CH3), 
29.54 (2 C, piperidin-3-yl, piperidin-5-yl), 42.47 (1 C, NCH2), 52.23 (1 C, piperidin-4-yl), 52.62 
(2 C, piperidin-2-yl, piperidin-6-yl), 58.55 (1 C, NpiperidylCH2), 62.15 (1 C, OCH2), 98.52 (1 C, 
quinolin-3-yl), 109.30 (1 C, C-5), 115.47 (1 C, Ph), 116.58 (1 C, Ph), 116.73 (1 C, Ph), 120.47 
(1 C, Ph), 120.92 (1 C, Ph), 122.22 (1 C, Ph), 123.09 (1 C, Ph), 126.70 (1 C, Ph), 133.60 (1 C, 
Ph), 137.68 (1 C, C-6), 138.82 (1 C, Ph), 145.33 (1 C, Ph), 150.90 (1 C, Ph), 151.05 (1 C, C-
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2), 155.84 (1 C, quinolin-4-yl), 163.93 (1 C, C-4), 165.95 (1 C, COPh), C (quinolin-2-yl) could 
not be observed. HRMS (ESI): m/z [M + H]+ Calcd. for [C29H31N5O6 + H]+ 546.2347, found 
546.2248. 
4-((2-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)quinolin-4-
yl)oxy)phenyl 3,4-dihydroxybenzoate (20) 3,4-Bis((tert-butyldimethylsilyl)oxy)benzoic acid was 
synthesized accoding to the literature [55]. To a solution of 7 (0.24 g, 0.52 mmol) and 3,4-
bis((tert-butyldimethylsilyl)oxy)benzoic acid (0.21 g, 0.55 mmol) in CH2Cl2 (50 mL) were added 
EDC.HCl (0.20 g, 1.0 mmol) and DMAP (6.4 mg, 0.052 mmol) and the resulting solution was 
stirred at room temperature overnight to yield the imtermediate (0.14 g, 0.17 mmol), which was 
treated with HF.Pyridine (0.33 mL, 0.96 mL/mmol TBDMS) in pyridine (0.33 mL, 0.96 mL/mmol 
TBDMS)/THF (0.68 mL, 2.0 mL/mmol TBDMS) to give 20 (eluent system: 5% methanol in 
CH2Cl2, 48 mg, 16%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.55 - 1.81 (m, 7 H, 5-CH3, 
piperidin-3-yl, piperidin-5-yl), 2.07 - 2.19 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.83 - 2.93 
(m, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.68 (s, 2 H, NpiperidylCH2), 4.18 - 4.31 (m, 1 H, piperidin-
4-yl), 6.84 (s, 1 H, quinolin-3-yl), 6.86 - 6.91 (m, 1 H, Ph), 7.32 - 7.43 (m, 4 H, Ph), 7.45 - 7.53 
(m, 3 H, H-6, Ph), 7.61 (ddd, J = 8.2, 6.9, 1.0 Hz, 1 H, Ph), 7.79 (ddd, J = 8.3, 6.9, 1.5 Hz, 1 H, 
Ph), 7.98 (d, J = 8.2 Hz, 1 H, Ph), 8.26 (dd, J = 8.2, 0.9 Hz, 1 H, Ph), 9.75 (s, 2 H, OH), 11.17 
(br. s., 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.03 (1 C, 5-CH3), 29.97 (2 C, piperidin-
3-yl, piperidin-5-yl), 52.15 (1 C, piperidin-4-yl), 52.56 (2 C, piperidin-2-yl, piperidin-6-yl), 63.93 
(1 C, NpiperidylCH2), 103.88 (1 C, quinolin-3-yl), 108.93 (1 C, C-5), 115.51 (1 C, Ph), 116.78 (1 C, 
Ph), 119.28 (1 C, Ph), 120.06 (1 C, Ph), 121.38 (1 C, Ph), 121.65 (2 C, Ph), 122.75 (1 C, Ph), 
124.00 (2 C, Ph), 126.11 (1 C, Ph), 128.50 (1 C, Ph), 130.35 (1 C, Ph), 137.36 (1 C, C-6), 
145.34 (1 C, Ph), 147.95 (1 C, Ph), 148.62 (1 C, Ph), 150.79 (1 C, Ph), 151.40 (1 C, C-2), 
151.57 (1 C, Ph), 160.88 (1 C, quinolin-2-yl), 161.25 (1 C, quinolin-4-yl), 163.63 (1 C, COPh), 
164.54 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C33H30N4O7 + H]+ 595.2187, found 
595.2189. 
N-hydroxy-4-((2-((4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)methyl)quinolin-4-yl)oxy)benzamide (21) To a solution of 8 (0.10 g, 0.21 mmol) and O-
benzylhydroxylamine hydrochloride (34 mg, 0.21 mmol) in CH2Cl2 (50 mL) were added 
EDC.HCl (79 mg, 0.41 mmol) and DMAP (2.5 mg, 0.020 mmol) and the resulting solution was 
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stirred at room temperature overnight to yield the intermediate (60 mg, 0.10 mmol). The 
intermediate and Pd/C were dissolved in ethanol and the mixture was stirred under hydrogen 
to give 21 (eluent system: 8% methanol in CH2Cl2, 21 mg, 20%). 1H NMR (300 MHz, DMSO-
d6) δ ppm 1.47 - 1.92 (m, 7 H, 5-CH3, piperidin-3-yl, piperidin-5-yl), 2.01 - 2.21 (m, 2 H, piperidin-
2a-yl, piperidin-6a-yl), 2.89 (d, J = 10.8 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.70 (s, 2 H, 
NpiperidylCH2), 4.16 - 4.30 (m, 1 H, piperidin-4-yl), 6.91 (s, 1 H, quinolin-3-yl), 7.27 - 7.37 (m, 2 H, 
Ph), 7.54 (s, 1 H, H-6), 7.61 (ddd, J = 8.2, 6.9, 1.0 Hz, 1 H, Ph), 7.80 (ddd, J = 8.4, 6.9, 1.5 Hz, 
1 H, Ph), 7.86 - 7.92 (m, 2 H, Ph), 8.00 (d, J = 7.9 Hz, 1 H, Ph), 8.17 (d, J = 8.2 Hz, 1 H, Ph), 
9.06 (s, 1 H, NHOH), 11.16 (s, 1 H, NH), 11.28 (br. s., 1 H, NHOH). 13C NMR (75 MHz, DMSO-
d6) δ ppm 11.97 (1 C, 5-CH3), 29.85 (2 C, piperidin-3-yl, piperidin-5-yl), 52.26 (1 C, piperidin-4-
yl), 52.59 (2 C, piperidin-2-yl, piperidin-6-yl), 63.99 (1 C, NpiperidylCH2), 105.47 (1 C, quinolin-3-
yl), 108.95 (1 C, C-5), 115.04 (1 C, Ph), 119.71 (2 C, Ph), 120.29 (1 C, Ph), 121.33 (1 C, Ph), 
126.32 (1 C, Ph), 128.61 (1 C, Ph), 129.37 (1 C, Ph), 129.50 (1 C, Ph), 130.44 (1 C, Ph), 137.56 
(1 C, C-6), 148.73 (1 C, Ph), 150.78 (1 C, C-2), 156.93 (1 C, Ph), 160.13 (1 C, CONH), 160.87 
(1 C, quinolin-2-yl), 163.64 (1 C, C-4), C (quinolin-4-yl) could not be observed. HRMS (ESI): 
m/z [M + H]+ Calcd. for [C27H27N5O5 + H]+ 502.2085, found 502.2238. 
Methyl (E)-2-(2-hydroxy-4-((2-((4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-
1-yl)methyl)quinolin-4-yl)oxy)benzylidene)hydrazine-1-carbodithioate (22) Following General 
procedure 2, 3 (0.14 g, 0.28 mmol) and 2,4-dihydroxybenzaldehyde (57 mg, 0.42 mmol) in EA 
(2.0 mL) afforded the protected intermediate. The intermediate (0.10 g, 0.16 mmol) was heated 
in TFA (2.0 mL) at 73 ℃ for 4 h, followed by concentration in vacuo to give the deprotected 
compound, which was further refluxed with methyl hydrazinecarbodithioate (5.0 mg, 0.041 
mmol, synthesized according to literature [42]) in methanol (20 mL) to yield 22 (eluent system: 
5% methanol in CH2Cl2, 9.4 mg, 6%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.68 - 1.94 (m, 5 
H, 5-CH3, piperidin-3a-yl, piperidin-5a-yl), 2.03 - 2.25 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 
2.53 (s, 3 H, SCH3), 4.32 - 4.65 (m, 3 H, piperidin-4-yl, NpiperidylCH2), 6.79 - 6.91 (m, 2 H, Ph), 
7.01 (s, 1 H, quinolin-3-yl), 7.46 (s, 1 H, H-6), 7.71 (t, J = 7.5 Hz, 1 H, Ph), 7.80 - 7.97 (m, 2 H, 
Ph), 8.10 (d, J = 8.5 Hz, 1 H, Ph), 8.28 (d, J = 8.2 Hz, 1 H, Ph), 8.57 (s, 1 H, CHN), 10.86 (s, 1 
H, OH), 11.28 (s, 1 H, CONH), 13.36 (br. s., 1 H, NHCS). H (piperidin-2-yl, piperidin-6-yl) were 
hidden in the broad solvent peak. 13C NMR (75 MHz, DMSO-d6) δ ppm 12.15 (1 C, 5-CH3), 
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16.76 (1 C, SCH3), 26.95 (2 C, piperidin-3-yl, piperidin-5-yl), 50.18 (1 C, piperidin-4-yl), 51.62 
(2 C, piperidin-2-yl, piperidin-6-yl), 59.23 (1 C, NpiperidylCH2), 105.57 (1 C, quinolin-3-yl), 108.08 
(1 C, Ph), 109.23 (1 C, C-5), 111.97 (1 C, Ph), 117.16 (1 C, Ph), 120.19 (1 C, Ph), 121.57 (1 C, 
Ph),127.12 (1 C, Ph), 128.53 (1 C, Ph), 128.83 (1 C, Ph), 131.05 (1 C, Ph), 137.20 (1 C, C-6), 
143.27 (1 C, CHN), 148.51 (1 C, Ph), 150.71 (1 C, C-2), 156.93 (1 C, Ph), 158.94 (1 C, COH), 
160.88 (1 C, quinolin-2-yl), 163.61 (1 C, C-4), 197.34 (1 C, CS), C (quinolin-4-yl) could not be 
observed. HRMS (ESI): m/z [M + H]+ Calcd. for [C29H30N6O4S2 + H]+ 591.1843, found 591.1840. 
1-(1-(6-Chloro-2-ethylimidazo[1,2-a]pyridine-3-carbonyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (23) 6-Chloro-2-ethylimidazo[1,2-a]pyridine-3-carboxylic acid was synthesied 
accordign to a literature procedure [32]. To a solution of 6-chloro-2-ethylimidazo[1,2-a]pyridine-
3-carboxylic acid (0.30 g, 1.3 mmol) and 5 (0.29 g, 0.89 mmol) in DMF (10 mL) were added 
EDC.HCl (0.34 g, 1.78 mmol), hydroxybenzotriazole (60 mg, 0.44 mmol) and triethylamine (0.25 
mL, 1.8 mmol) and the resulting solution was heated at 70 ℃ for 4 h to give the BOM protected 
amide, which was heated at 73 ℃ in TFA (4.0 mL) for 4 h to yield 23 (eluent system: 5% 
methanol in CH2Cl2, 79 mg, 21%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.28 (t, J = 7.5 Hz, 3 
H, CH2CH3), 1.73 - 1.98 (m, 7 H, 5-CH3, piperidin-3-yl, piperidin-5-yl), 2.77 (q, J = 7.5 Hz, 2 H, 
CH2CH3), 3.09 - 3.23 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 4.18 (d, J = 12.6 Hz, 2 H, 
piperidin-2b-yl, piperidin-6b-yl), 4.50 - 4.61 (m, 1 H, piperidin-4-yl), 7.46 (dd, J = 9.7, 2.1 Hz, 1 
H, Py), 7.50 (s, 1 H, H-6), 7.66 (d, J = 9.4 Hz, 1 H, Py), 8.59 (s, 1 H, Py), 10.92 (br. s., 1 H, NH). 
13C NMR (75 MHz, DMSO-d6) δ ppm 12.09 (1 C, 5-CH3), 12.78 (1 C, CH2CH3), 20.44 (1 C, 
CH2CH3), 30.0 (2 C, piperidin-3-yl, piperidin-5-yl), 43.97 (2 C, piperidin-2-yl, piperidin-6-yl), 
51.78 (1 C, piperidin-4-yl), 108.99 (1 C, C-5), 116.12 (1 C, Py), 120.67 (1 C, (Cl)Py), 124.90 (1 
C, Py), 128.71 (1 C, Py), 137.47 (1 C, C-6), 142.21 (1 C, Py), 146.31 (1 C, (CH2)Cimidazole), 
150.74 (1 C, C-2), 159.79 (1 C, CO), 163.64 (1 C, C-4), C (Cimidazole(CO)) could not be observed. 
HRMS (ESI): m/z [M + H]+ Calcd. for [C20H22ClN5O3 + H]+ 416.1484, found 416.1474. 
4-(4-(3-((Benzyloxy)methyl)-5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)benzonitrile (24) 24 was synthesized according to a literature reported procedure [32]. To a 
solution of 5 (0.50 g, 1.5 mmol) and 4-fluorobenzonitrile (0.20 g, 1.7 mmol) in DMSO was added 
K2CO3 (0.42 g, 3.0 mmol) and the resulting solution was heated at 120 ℃ overnight. After 
cooling down to room temperature, water (20 mL) was addded to the reaction mixture, followed 
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by filtration. The cake was collected and purified to yield 24 (eluent system: 50% EA in 
petroleum ether, 0.27 g, 41%). 1H NMR (300 MHz, CDCl3) δ ppm 1.76 - 2.00 (m, 7 H, 5-CH3, 
piperidin-3-yl, piperidin-5-yl), 2.97 - 3.11 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 4.00 (d, J = 
13.2 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 4.68 - 4.84 (m, 3 H, (Ph)CH2, piperidin-4-yl), 5.53 
(s, 2 H, N3CH2), 6.87 - 6.98 (m, 3 H, Ph, H-6), 7.22 - 7.42 (m, 5 H, Ph), 7.49 - 7.56 (m, 2 H, Ph). 
13C NMR (75 MHz, CDCl3) δ ppm 13.25 (1 C, 5-CH3), 30.04 (2 C, piperidin-3-yl, piperidin-5-yl), 
47.50 (2 C, piperidin-2-yl, piperidin-6-yl), 53.13 (1 C, piperidin-4-yl), 70.87 (1 C, N3CH2), 72.28 
(1 C, (Ph)CH2), 101.04 (1 C, Ph), 110.51 (1 C, C-5), 114.88 (2 C, Ph), 119.69 (1 C, CN), 127.61 
(3 C, Ph), 128.25 (2 C, Ph), 133.67 (2 C, Ph), 134.45 (1 C, C-6), 137.98 (1 C, Ph), 151.47 (1 C, 
C-2), 152.37 (1 C, Ph), 163.09 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C25H26N4O3 + 
H]+ 431.2078, found 431.2096. 
4-((4-(3-((Benzyloxy)methyl)-5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)methyl)benzonitrile (25) To a solution of 4-formylbenzonitrile (0.30 g , 2.3 mmol) and 5 (0.50 
g, 1.5 mmol) in 1,2-dichloroethane (20 mL) was added sodium triacetoxyborohydride (0.65 g, 
3.1 mmol) and the resulting solution was stirred at room temperature overnight. The reaction 
mixture was washed with sat. NaHCO3 (50 mL), brine (50 mL), and dreid over Na2SO4. The 
concentrated residue was purified by column chromatography to yield 25 (eluent system: 50% 
EA in petroleum ether, 0.32 g, 46%). 1H NMR (300 MHz, CDCl3) δ ppm 1.79 - 1.94 (m, 7 H, 5-
CH3, piperidin-3-yl, piperidin-5-yl), 2.16 - 2.31 (m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.98 (d, 
J = 11.7 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.61 (s, 2 H, NpiperidylCH2), 4.49 - 4.63 (m, 1 H, 
piperidin-4-yl), 4.71 (s, 2 H, (Ph)CH2), 5.51 (s, 2 H, N3CH2), 7.05 (d, J = 1.2 Hz, 1 H, H-6), 7.22 
- 7.38 (m, 5 H, Ph), 7.48 (d, J = 8.2 Hz, 2 H, Ph), 7.58 - 7.67 (m, 2 H, Ph). 13C NMR (75 MHz, 
CDCl3) δ ppm 13.22 (1 C, 5-CH3), 30.57 (2 C, piperidin-3-yl, piperidin-5-yl), 52.68 (2 C, 
piperidin-2-yl, piperidin-6-yl), 52.98 (1 C, piperidin-4-yl), 61.91 (1 C, NpiperidylCH2), 70.81 (1 C, 
N3CH2), 72.20 (1 C, (Ph)CH2), 110.12 (1 C, C-5), 111.15 (1 C, Ph), 118.73 (1 C, CN), 127.55 (3 
C, Ph), 128.19 (2 C, Ph), 129.44 (2 C, Ph), 132.16 (2 C, Ph), 134.83 (1 C, C-6), 137.98 (1 C, 
Ph), 143.45 (1 C, Ph), 151.47 (1 C, C-2), 163.16 (1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. 
for [C26H28N4O3 + H]+ 445.2234, found 445.2187. 
6-Chloro-2-ethyl-N-(4-(4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide (26) 24 (0.50 g, 1.2 mmol) was heated in TFA 
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(8.0 mL) at 73 ℃ for 4 h, follwed by evaporation in vacuo to remove the volatile. According to 
a literature [56], the nitrile compound (0.30 g, 0.96 mmol) and CoCl2 (13 mg, 0.096 mmol) were 
dissolved in THF/water (4.0 mL/2.0 mL) at 0 ℃ with ice bath. NaBH4 (73 mg, 1.9 mmol) was 
added in 8 min and the mixture kept stirring for 2 h. The reaction mixture was filtered through 
celite to remove the dark solid, and the filtrate was concentrated in vacuo to obtain oil, which 
was dried on oil pump overnight. The oil amine and 6-chloro-2-ethylimidazo[1,2-a]pyridine-3-
carboxylic acid (0.32 g, 1.4 mmol) were dissolved in DMF (20 mL), followed by addition of 
EDC.HCl (0.37 g, 1.9 mmol), hydroxybenzotriazole (65 mg, 0.48 mmol) and triethylamine (0.27 
mL, 1.9 mmol). After being heated at 70 ℃ for 4 h, the reaction mixture was evaporated in 
vacuo and purified to give 26 (eluent system: 5% methanol in CH2Cl2, 0.17 g, 28%). 1H NMR 
(300 MHz, DMSO-d6) δ ppm 1.24 (t, J = 7.5 Hz, 3 H, CH3CH2), 1.67 - 1.84 (m, 5 H, 5-CH3, 
piperidin-3a-yl, piperidin-5a-yl), 1.84 - 2.00 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 2.65 - 2.82 
(m, 2 H, piperidin-2a-yl, piperidin-6a-yl), 2.96 (q, J = 7.4 Hz, 2 H, CH3CH2), 3.77 (d, J = 12.6 
Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 4.33 - 4.47 (m, 3 H, PhCH2, piperidin-4-yl), 6.93 (d, J 
= 8.8 Hz, 2 H, Ph), 7.22 (d, J = 8.5 Hz, 2 H, Ph), 7.43 (dd, J = 9.5, 2.2 Hz, 1 H, Py), 7.60 - 7.67 
(m, 2 H, H-6, Py), 8.39 (t, J = 5.9 Hz, 1 H, CH2NH), 9.05 (dd, J = 2.2, 0.7 Hz, 1 H, Py), 11.20 (s, 
1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.00 (1 C, 5-CH3), 13.09 (1 C, CH3CH2), 21.85 
(1 C, CH3CH2), 29.80 (2 C, piperidin-3-yl, piperidin-5-yl), 41.92 (1 C, PhCH2), 48.61 (2 C, 
piperidin-2-yl, piperidin-6-yl ), 52.42 (1 C, piperidin-4-yl), 108.96 (1 C, C-5), 115.85 (1 C, 
Cimidazole(CO)), 116.06 (2 C, Ph), 117.18 (1 C, Py), 119.65 (1 C, (Cl)Py), 124.81 (1 C, Py), 127.02 
(1 C, Py), 128.26 (2 C, Ph), 129.68 (1 C, Ph), 137.68 (1 C, C-6), 143.25 (1 C, Py), 149.81 (1 C, 
Ph), 150.84 (1 C, (CH2)Cimidazole), 150.96 (1 C, C-2), 160.44 (1 C, CONH), 163.69 (1 C, C-4). 
HRMS (ESI): m/z [M + H]+ Calcd. for [C27H29ClN6O3 + H]+ 521.2063, found 521.2056. 
N-(4-(4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)benzyl)-3,5-
dinitrobenzamide (27) Following the same procedure as 26, 24 (0.30 g, 0.70 mmol) was used 
as staring material. After being heated in TFA (4.0 mL) at 73 ℃ for 4 h, the deprotected 
intermediate and CoCl2 (5.86 mg, 0.045 mmol) were dissolved in THF/water (4.0 mL/2.0 mL) 
with ice bath, followed by addition of NaBH4 (34 mg, 0.90 mmol) and the resulting mixture kept 
stirring for 2 h. The reaction mixture was filtered through celite to remove the dark solid, and 
the filtrate was concentrated in vacuo to obtain oil, which was dried on oil pump overnight. To 
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a solution of dried amine and 3.5-dinitrobenzoic acid (0.14 g, 0.67 mmol) in DMF (10 mL) were 
added EDC.HCl (0.17 g, 0.89 mmol), hydroxybenzotriazole (30 mg, 0.22 mmol) and 
triethylamine (0.13 mL, 0.89 mmol). After being heated at 70 ℃ for 4 h, the reaction mixture 
was evaporated in vacuo and purified to give 27 (eluent system: 5% methanol in CH2Cl2, 58 
mg, 16%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.72 - 1.80 (m, 5 H, 5-CH3, piperidin-3a-yl, 
piperidin-5a-yl), 1.84 - 1.99 (m, 2 H, piperidin-3b-yl, piperidin-5b-yl), 2.69 - 2.79 (m, 2 H, 
piperidin-2a-yl, piperidin-6a-yl), 3.77 (d, J = 12.6 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 4.33 
- 4.49 (m, 3 H, piperidin-4-yl, PhCH2), 6.94 (d, J = 8.5 Hz, 2 H, Ph), 7.21 (d, J = 8.8 Hz, 2 H, 
Ph), 7.62 (d, J = 0.9 Hz, 1 H, H-6), 8.94 (t, J = 2.2 Hz, 1 H, Ph), 9.07 (d, J = 2.1 Hz, 2 H, Ph), 
9.63 (t, J = 5.7 Hz, 1 H, CH2NH), 11.20 (s, 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 12.00 
(1 C, 5-CH3), 29.76 (2 C, piperidin-3-yl, piperidin-5-yl), 42.73 (1 C, PhCH2), 48.61 (2 C, 
piperidin-2-yl, piperidin-6-yl), 52.44 (1 C, piperidin-4-yl), 108.97 (1 C, C-5), 116.08 (2 C, Ph), 
120.84 (1 C, Ph), 127.54 (2 C, Ph), 128.57 (2 C, Ph), 128.99 (1 C, Ph), 136.90 (1 C, Ph), 137.68 
(1 C, C-6), 148.21 (2 C, Ph), 150.01 (1 C, Ph), 150.84 (1 C, C-2), 161.90 (1 C, CONH), 163.69 
(1 C, C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C24H24N6O7 + H]+ 509.1779, found 509.1778. 
N-(4-((4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)benzyl)-3,5-
dinitrobenzamide (28) Following the same procedure as 26, 25 (0.40 g, 0.90 mmol) was used 
as staring material. After being heated in TFA (4.0 mL) at 73 ℃ for 4 h, the deprotected 
intermediate and CoCl2 (10 mg, 0.077 mmol) were dissolved in THF/water (4.0 mL/2.0 mL) with 
ice bath, followed by addition of NaBH4 (58 mg, 1.5 mmol) and the resulting solution kept stirring 
for 2 h. The reaction mixture was filtered through celite to remove the dark solid, and the filtrate 
was concentrated in vacuo to obtain oil, which was dried on oil pump overnight. To a solution 
of dried amine and 3.5-dinitrobenzoic acid (97 mg, 0.46 mmol) in DMF (10 mL) were added 
EDC.HCl (0.12 g, 0.60 mmol), hydroxybenzotriazole (20 mg, 0.15 mmol) and triethylamine (85 
μl, 0.61 mmol). After being heated at 70 ℃ for 4 h, the reaction mixture was evaporated in 
vacuo and purified to give 28 (eluent system: 5% methanol in CH2Cl2, 47 mg, 10%). 1H NMR 
(300 MHz, DMSO-d6) δ ppm 1.56 - 1.68 (m, 2 H, piperidin-3a-yl, piperidin-5a-yl), 1.72 - 1.85 (m, 
5 H, 5-CH3, piperidin-3b-yl, piperidin-5b-yl), 2.01 (t, J = 10.8 Hz, 2 H, piperidin-2a-yl, piperidin-
6a-yl), 2.87 (d, J = 11.1 Hz, 2 H, piperidin-2b-yl, piperidin-6b-yl), 3.44 (s, 2 H, NpiperidylCH2), 4.17 
- 4.28 (m, 1 H, piperidin-4-yl), 4.52 (d, J = 5.6 Hz, 2 H, PhCH2), 7.21 - 7.34 (m, 4 H, Ph), 7.60 
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(d, J = 1.2 Hz, 1 H, H-6), 8.94 (t, J = 2.1 Hz, 1 H, Ph), 9.05 - 9.10 (m, 2 H, Ph), 9.70 (t, J = 5.9 
Hz, 1 H, CH2NH), 11.15 (br. s., 1 H, NH). 13C NMR (75 MHz, DMSO-d6) δ ppm 11.99 (1 C, 5-
CH3), 29.97 (2 C, piperidin-3-yl, piperidin-5-yl), 42.98 (1 C, PhCH2), 52.30 (2 C, piperidin-2-yl, 
piperidin-6-yl), 52.39 (1 C, piperidin-4-yl), 61.42 (1 C, NpiperidylCH2), 108.90 (1 C, C-5), 120.90 
(1 C, Ph), 127.43 (2 C, Ph), 127.57 (2 C, Ph), 128.90 (2 C, Ph), 136.78 (1 C, Ph), 137.34 (2 C, 
Ph), 137.68 (1 C, C-6), 148.21 (2 C, Ph), 150.79 (1 C, C-2), 162.09 (1 C, CONH), 163.66 (1 C, 
C-4). HRMS (ESI): m/z [M + H]+ Calcd. for [C25H26N6O7 + H]+ 523.1936, found 523.1956. 
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